drugset / Trial / NCT04817657

Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician Use

NCT04817657

Expanded access No longer available Janssen Research & Development, LLC

Summary

The purpose of this Pre-approval access (PAA) program is to provide VAC31518 (Ad26.CoV2.S) vaccine for the prevention of coronavirus disease-2019 (COVID-19) infection. This PAA program may be considered to protect participants against a serious/life-threatening diseases or conditions, where there are no alternative treatments available.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ad26.COV2.S Vaccine 0.5 ml Intramuscular

Indications

No indication recorded.